PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5750083

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MAGNUS OXYGEN LIMITED	10/19/2017

RECEIVING PARTY DATA

Name:	MERVYN SINGER
Street Address:	16 COPPICE WALK, TOTTERIDGE
City:	LONDON
State/Country:	ENGLAND
Postal Code:	N20 8BZ
Name:	ALEX DYSON
Street Address:	39 PALMERSTON ROAD
City:	LONDON
State/Country:	ENGLAND
Postal Code:	N22 8QH

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13630180

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3523758100
Email: DRS@SLEPATENTS.COM
Correspondent Name: DAVID R. SALIWANCHIK
Address Line 1: P.O. BOX 142950
Address Line 4: GAINESVILLE, FLORIDA 32614-2950

ATTORNEY DOCKET NUMBER:	GJE.8666C1
NAME OF SUBMITTER:	DAVID R. SALIWANCHIK
SIGNATURE:	/DAVID R. SALIWANCHIK/
DATE SIGNED:	10/02/2019

Total Attachments: 17

source=1-exAssign-MO-MS-AD#page1.tif
source=1-exAssign-MO-MS-AD#page2.tif
source=1-exAssign-MO-MS-AD#page3.tif
source=1-exAssign-MO-MS-AD#page4.tif
source=1-exAssign-MO-MS-AD#page5.tif
source=1-exAssign-MO-MS-AD#page6.tif
source=1-exAssign-MO-MS-AD#page7.tif
source=1-exAssign-MO-MS-AD#page8.tif
source=1-exAssign-MO-MS-AD#page9.tif
source=1-exAssign-MO-MS-AD#page10.tif
source=1-exAssign-MO-MS-AD#page11.tif
source=1-exAssign-MO-MS-AD#page12.tif
source=1-exAssign-MO-MS-AD#page13.tif
source=1-exAssign-MO-MS-AD#page14.tif
source=1-exAssign-MO-MS-AD#page15.tif
source=1-exAssign-MO-MS-AD#page16.tif
source=1-exAssign-MO-MS-AD#page17.tif

ASSIGNMENT AGREEMENT

between

Magnus Oxygen Limited

and

Mervyn Singer

and

Alex Dyson

Dated: 19th October 2012

INDEX

THIS AGREEMENT is made the 19th day of October 2017

BETWEEN:

(1) **MAGNUS OXYGEN LIMITED**, a company incorporated in England with company number 08698373, whose registered address is 26 Red Lion Square, London, England, WC1R 4AG (the "**Company**");

and

(2) **PROFESSOR MERVYN SINGER**, whose home address is at 16 Coppice Walk, Totteridge, London, England, N20 8BZ;

(3) **DOCTOR ALEX DYSON**, whose home address is at 39 Palmerston Road, London, England N22 8QH

(each an "**Inventor**" and together, the "**Inventors**").

WHEREAS:

A. The Inventors are directors of the Company, and invented and developed technology, materials and/or know-how relating to the technology described in Schedule 1 (the "**Technology**"). The Technology includes specific items of intellectual property described in Schedule 2, including the various patents and patent applications, the entire portfolio of which was assigned to the Company under an assignment agreement dated 19 October 2017 and all related data and intellectual property rights, including (but not limited to) know how and trade secrets, relating to the Technology (the "**Assigned Property**").

B. UCL Business PLC ("**UCLB**") wishes to take an assignment of the Assigned Property but due to the relationship between the Company and UCLB, UCLB requires that the Company first assigns the Assigned Property to the Inventors, who will subsequently assign the Assigned Property to UCLB. UCLB will then fund the development of the Technology as described in clause 4 of this agreement (the "**Funding**").

C. For the purpose of securing the Funding for the further development of the Technology, the Company now wishes to assign back to the Inventors, in equal shares, all of its right, title and interest in the Technology, and the Inventors wish to take an assignment of the Technology in equal shares, subject to and in accordance with the provisions of this Agreement.

D. The Company and the Inventors have agreed the terms of a revenue sharing agreement to be entered into by the Company and the Inventors on the same date as this Agreement and relating to the continued exploitation of the Technology (the "**Revenue Sharing Agreement**").

NOW IT IS AGREED as follows:

1. ASSIGNMENT

1.1 In consideration of the Inventors executing the Revenue Sharing Agreement and the sum of £1 (one pound sterling) now paid by each of the Inventors to the Company (receipt and sufficiency of which is hereby acknowledged), the Company hereby assigns and transfers to the Inventors in equal shares, absolutely with full title guarantee all of its right, title and interest in the Assigned Property, including (if applicable):

1.1.1 in respect of any and each patent comprised within the Assigned Property which has at the date of this agreement been granted ("**Patent**"):

(i) the right to claim priority from such Patent;

(ii) the right to file divisional applications based thereon and to prosecute and obtain grant of patent on each and any such divisional application;

(iii) the right to extend to or register in, or in respect of, any country or territory in the world each and any of the Patents or any patents granted on any such divisional applications;

(iv) the right to extend the term of any Patents or any divisionals thereof; and

(v) the right to elect to reject or submit to the competence of the Unitary Patent Court in respect of any Patent pursuant to Article 83(3) of the Agreement on a Unified Patent Court (2013/C 175/01) or to validate any such Patent as a patent that has unitary effect by virtue of Regulation (EU) No 1257/2012.

1.1.2 in respect of any and each patent application comprised within the Assigned Property ("**Patent Applications**"):

(i) the right to claim priority from, and to prosecute and obtain grant of patent on, such Patent Application;

(ii) the right to file divisional applications based thereon and to prosecute and obtain grant of patent on each and any such divisional application;

(iii) the right to extend to or register in, or in respect of, any country or territory in the world each and any of the Patent Applications, and any patents granted on any such Patent Applications or any divisionals thereof;

(iv) the right to extend the term of any patents granted on any Patent Applications or any divisionals thereof;

3)

(v) the absolute entitlement to any patents granted pursuant to any Patent Applications, any patents granted on any such Patent Applications, or any divisionals thereof; and

(vi) the right to elect to reject or submit to the competence of the Unitary Patent Court in respect of any patent granted pursuant to any Patent Application pursuant to Article 83(3) of the Agreement on a Unified Patent Court (2013/C 175/01) or to validate any such patent as a patent that has unitary effect by virtue of Regulation (EU) No 1257/2012;

1.1.3 In respect of any and each Patent and Patent Application comprised within the Assigned Property, all rights to bring or defend any claims, actions or proceedings (and to retain any damages recovered), and/or to appeal any award or judgements issued, in respect of any infringement or challenge to validity or entitlement, or any other cause of action arising from ownership, of the Patents, the Patent Applications, or any patents granted pursuant to such Patent Applications, or any divisionals thereof, whether occurring before on or after the date of this Agreement;

1.1.4 In respect of each and any invention disclosed or comprised within the Technology, the right to file patent applications for such invention in or in respect of any country or territory in the world.

1.2 To the extent that the Assigned Property includes any know-how and technical information protected under the laws governing confidential information and/or trade secrets protected by the EU Trade Secrets Directive (Directive 2016/943):

1.2.1 the Company hereby transfers to the Inventors such rights as it may have in law to prevent the unlawful or unauthorised acquisition, use or disclosure of or access to such know-how, technical information and trade secrets;

1.2.2 to the extent that such rights cannot be, or are not, transferred by virtue of the provisions of Clause 1.2.1, the Company agrees to be joined in any action (whether as claimant or otherwise) brought by the Inventors or its nominee, or to raise proceedings in its own name if required, against any third party that is alleged to have unlawfully acquired, accessed, used or disclosed any trade secret or to be making unauthorised use of, or to have disclosed in breach of an obligation of confidentiality, the know-how and technical information, subject to the Inventors reimbursing the Company for any damages, costs and expenses actually and reasonably incurred in relation to any such action;

1.2.3 subject to Clause 4, and for so long as each of the know-how, technical information and trade secrets remains confidential and is not publicly known (other than as a result of breach of this Clause 1.2.3 by the Company), the Company will neither use

nor disclose any such know-how, technical information and trade secrets without the prior written consent of the Inventors;

1.2.4 the Company warrants that it is not aware of any disclosure of such know-how, technical information and trade secrets to any third party, prior to the date of this Agreement, except under written obligations of confidentiality;

1.2.5 the Company warrants to the Inventors that none of the know-how, technical information or trade secrets constitutes personal data or personally identifiable information; and

1.2.6 if required to do so by the Inventors, the Company will make such acknowledgements to third parties as the Inventors may reasonably require stating that the Inventors own all right in and to such know-how, technical information and trade secrets and that the Company does not retain any ownership rights in such know-how, technical information and trade secrets.

1.3 The Company shall provide to the Inventors (promptly on request) all information and documentation and give such assistance (including executing and delivering documents) as the Inventors may require at the expense of the Inventors for the purpose of giving full effect to this agreement, including:

1.3.1 to secure the vesting in the Inventors of all rights in the Technology;

1.3.2 to uphold the Inventors rights in the Technology including the bringing of any actions as contemplated by Clause 1.2.2; and

1.3.3 to bring, make, oppose or defend any claims, actions or challenge to the entitlement, validity or ownership of, and to resolve any questions concerning, the Technology.

2. WARRANTIES, REPRESENTATIONS AND UNDERTAKINGS

2.1 The Company hereby warrants and undertakes to the Inventors that:

2.1.1 so far as it is aware (having made no enquiry of any third parties or conducted any freedom to operate searches), use and exploitation of the Technology will not infringe the intellectual property rights of any third party;

2.1.2 so far as it is aware (having not made any enquiries of any third parties), the Technology is not subject to any claims, proceedings, challenges or litigation (whether actual, pending or threatened) relating to ownership or validity and is not subject to any third party right or encumbrances;

2.1.3 it has not by act or omission caused or permitted anything which might jeopardise the registration or enforceability or application for registration of any registerable intellectual property comprised within the Technology;

2.1.4 all costs associated with the maintenance and prosecution of the Patents and Patent Applications up to the date of this agreement have been paid by the Company;

2.1.5 it has not been and is not currently a party to any agreement or understanding, whether oral or written which would in any manner be inconsistent with the assignment of rights provided for in this Agreement;

2.1.6 during the term of this agreement it shall not enter into any agreement or understanding, oral or written, nor engage in any activity, which would in any manner be inconsistent with the provisions of this Agreement; and

2.1.7 all materials described in Schedule 1 (if any) have been obtained in compliance with all ethical and legal requirements (including applicable data privacy laws, including the Data Protection Act 1998).

2.2 Each Inventor acknowledges and agrees that he is aware of all persons who might have rights in the Technology, including any other persons who were involved in developing the Technology, and any organisations that funded such development of the Technology.

2.3 The Inventors acknowledge and agree that they will be jointly and severally responsible for any costs associated with the maintenance and prosecution of the Patents and Patent Applications which fall due after the date of this agreement.

3. MORAL RIGHTS

The Company has obtained irrevocable and unconditional waivers of any moral rights in the Technology to which any of the Company's employees may now or at any future time be entitled under Chapter IV of the Copyright Designs and Patents Act 1988 or any similar provisions of law in any jurisdiction, including the right to be identified, the right of integrity and the right against false attribution.

4. FUNDING AND RESERVATION OF RIGHTS

4.1 The assignment of the Assigned Property herein is for the purpose of the Inventors assigning the Assigned Property to UCLB, which has agreed to contribute in the region of £150,000 ("**Initial Funding**") from Apollo Therapeutics ("Apollo"), the full amount of which shall be paid by no later than 1 August 2018 ("**Initial Funding Date**") to further develop the Technology. In the event that the Initial Funding is not received by the Initial Funding Date, the Inventors shall assign the Assigned Property back to the Company, and shall do all acts reasonably requested by the Company to effect the assignment back to the Company of the Assigned Property.

4.2 In addition to the Initial Funding, UCLB will seek a further funding from its Apollo Fund ("**Apollo Funding**") of no less than £1.75 million pounds sterling to invest in the further development of the Technology following the Initial Funding. In the event that UCLB is unable to secure the

Apollo Funding by 1 August 2019 ("**Apollo Funding Date**"), the parties agree that the Inventors shall permit UCLB to obtain alternative funding of no less than £1.75 million pounds sterling ("**Alternative Funding**"), provided the Alternative Funding is fully committed within 12 months of the Apollo Funding Date ("**Alternative Funding Date**").

4.3 In the event that UCLB does not secure the Apollo Funding by the Apollo Funding Date or the Alternative Funding by the Alternative Funding Date, of it UCLB decides not to seek the Alternative Funding, the Inventors shall assign the Assigned Property back to the Company, and the Inventors shall do all acts reasonably requested by the Company to effect the assignment back to the Company of the Assigned Property.

4.4 If UCLB successfully obtains the Apollo Funding, but the Apollo Fund decides within two years of the Apollo Funding Date not to continue investing in the development of the Technology, the parties agree that UCLB shall be permitted to seek additional funding from third parties of no less than £1.75 million, or such other greater amount as may be necessary to fund a Phase II clinical trial of the Technology ("**Phase II Funding**").

4.5 The parties agree that, should the Phase II Funding not be obtained within three years of the Apollo Funding Date or two years of the Alternative Funding Date, the Inventors shall assign the Assigned Property back to the Company, and the Inventors shall do all acts reasonably requested by the Company to effect the assignment back to the Company of the Assigned Property.

4.6 The Inventors warrant that they shall ensure any agreements entered into between the Inventors and UCLB shall contain substantially similar provisions to give full effect to this clause 4.

4.7 Any assignment of the Assigned Property back to the Company under clauses 4.1, 4.3 and/or 4.5 shall include the assignment of any new intellectual property rights created or developed or used by the Inventors and/or UCLB after the date of this agreement which relate to or are necessary for the further development of the Technology.

4.8 The Company shall have the non-exclusive, irrevocable, worldwide, royalty-free right to use the Technology for the Company's own internal research.

5. GENERAL

5.1 **Amendment.**

This agreement may only be amended in writing signed by duly authorised representatives of the Company and the Inventors.

5.2 **Assignment.**

The Company shall not assign, mortgage, charge or otherwise transfer or deal with any rights or obligations under this agreement without the prior written consent of the Inventors.

5.3 **Waiver.**

Any waiver given under or in relation to this agreement shall be in writing and signed by or on behalf of the relevant party. No failure or delay on the part of any party to exercise any right or remedy under this agreement shall be construed or operate as a waiver thereof, nor shall any single or partial exercise of any right or remedy preclude the further exercise of such right or remedy.

5.4 **Invalid Clauses.**

If any provision or part of this agreement is held to be invalid, amendments to this agreement may be made by the addition or deletion of wording as appropriate to remove the invalid part or provision but otherwise retain the provision and the other provisions of this agreement to the maximum extent permissible under applicable law.

5.5 **No Agency.**

None of the parties shall act or describe itself as the agent of any other party, nor shall any party make or represent that it has authority to make any commitments on any of the other parties' behalf.

5.6 **Interpretation.**

In this agreement:

5.6.1 the headings are used for convenience only and shall not affect its interpretation;

5.6.2 references to persons shall include incorporated and unincorporated persons; references to the singular include the plural and vice versa; and references to the masculine include the feminine;

5.6.3 references to Clauses and Schedules mean clauses of, and schedules to, this agreement;

5.6.4 where the word "including" is used it shall be understood as meaning "including without limitation";

5.6.5 this agreement shall be binding on, and enure to the benefit of, each of the Inventors' respective successors, heirs and permitted assigns, and references to the Inventors shall include each of their respective successors, heirs and permitted assigns;

5.6.6 any reference to any English law term for any action, remedy, method or judicial proceeding, legal document, legal status, court, official or any legal concept or thing

shall in respect of any jurisdiction other than England be deemed to include what most nearly approximates in that jurisdiction to the English law term; and

5.6.7 time shall be of the essence in relation to the performance of the Inventor's obligations under this agreement.

5.7 **Law and Jurisdiction.**

The validity, construction and performance of this agreement, and any contractual and non-contractual claims arising hereunder, shall be governed by English law and shall be subject to the exclusive jurisdiction of the English courts to which the parties hereby submit.

5.8 **Entire Agreement.**

The parties acknowledge that they are not relying on any representation, agreement, term or condition which is not set out in this agreement. This agreement, including its Schedules, sets out the entire agreement between the parties relating to its subject matter and supersedes all prior oral or written agreements, arrangements or understandings between them relating to such subject matter. Nothing in this agreement will, however, operate to limit or exclude any liability for fraudulent misrepresentations.

5.9 **Third parties.**

Unless expressly stated otherwise, this agreement does not create any right enforceable by any person who is not a party to it ("Third Party") under the Contracts (Rights of Third Parties) Act 1999, but this Clause does not affect any right or remedy of a Third Party which exists or is available apart from that Act.

5.10 **Announcements.**

None of the parties shall make any press or other public announcement concerning any aspect of this agreement without the prior, express written consent of the other parties.

REST OF PAGE LEFT INTENTIONALLY BLANK

This agreement has been executed and takes effect on the date stated at the beginning of it.

By **Mervyn Singer**	By **Alex Dyson**	For and on behalf of **MAGNUS OXYGEN LIMITED**
Signature	Signature	Signature
MERVYN SINGER	ALEX DYSON	STEVENS SALES
Print name	Print name	Print name
Prof of Intensive Care Medicine	POST DOCTORAL RESEARCH FELLOW	Director
Job title	Job title	Job title
19 OCTOBER 2017	19/10/2017	19/10/2017
Date	Date	Date

SCHEDULE 1

GENERAL DESCRIPTION OF THE TECHNOLOGY

Reperfusion injury (e.g. following heart attack or stroke) is caused by excess production of damaging reactive oxygen species (ROS) due to influx of oxygen following revascularisation. The technology relates to a simple and innovative solution that is highly effective in a laboratory model of myocardial ischaemia/reperfusion injury. Our target population is patients undergoing coronary revascularisation for ST-segment elevation myocardial infarction. We made the novel discovery that a simple inorganic compound, ammonium tetrathiomolybdate (ATTM), used successfully as an unapproved copper chelator for Wilson's disease, is a sulphide donor. This decreases mitochondrial respiration/ROS production and, by releasing sulphide in a unique manner, provides greater efficacy and reduced toxicity over standard sulphide donors. The technology relates to primary development of a novel polymorph of diethylamine tetrathiomolybdate (DEATTM) with therapeutic use of ammonium tetrathiomolybdate (ATTM) as a secondary option. The novel polymorph of DEATTM is synthesized using solid state materials in a process not previously described (Fig 1).



Fig 1: Synthesis of diethylamine tetrathiomolybdate (DEATTM).

SCHEDULE 2

SPECIFIC ITEMS OF INTELLECTUAL PROPERTY

A. All intellectual property rights related to the Technology, including any know how, trade secrets and technical information, and the following patent applications and patents:

Case Ref.	Instructor's Reference	Country	Application Date	Application No.	Publication No.	Registration Date	Registration No.	Case Status
REP08666BR	TTM for reperfusion injury	Brazil	30/03/2011	BR 11 2012 024704 2				Application filed
REP08666CN	TTM for reperfusion injury	China	30/03/2011	2011800168365	CN103096903A			Examination report received
REP08666EP	TTM for reperfusion injury of the brain	European Patent Office	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP Granted
REP08666EP/AT	TTM for reperfusion injury of the heart	Austria	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/AT1	TTM for reperfusion injury of the brain	Austria	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/BE	TTM for reperfusion injury of the heart	Belgium	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/BE1	TTM for reperfusion injury of the brain	Belgium	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/CH	TTM for reperfusion injury of the heart	Switzerland	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered

REP08666EP/CH1	TTM for reperfusion injury of the brain	Switzerland	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/CZ	TTM for reperfusion injury of the heart	Czech Republic	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/CZ1	TTM for reperfusion injury of the brain	Czech Republic	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/DE	TTM for reperfusion injury of the heart	Germany	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/DE1	TTM for reperfusion injury of the brain	Germany	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/DE2	TTM for reperfusion injury of the kidney - Magnus Oxygen	Germany	30/03/2011	14194820.8	2842562	27/04/2016	2842562	EP National Phase Entered
REP08666EP/DK	TTM for reperfusion injury of the heart	Denmark	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/DK1	TTM for reperfusion injury of the brain	Denmark	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/DK2	TTM for reperfusion injury of the kidney - Magnus Oxygen	Denmark	30/03/2011	14194820.8	2842562	27/04/2016	2842562	Granted/Registered
REP08666EP/ES	TTM for reperfusion injury of the heart	Spain	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/ES1	TTM for reperfusion injury of the brain	Spain	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/ES2	TTM for reperfusion injury of the kidney - Magnus Oxygen	Spain	30/03/2011	14194820.8	2842562	27/04/2016	2842562	Granted/Registered
REP08666EP/FI	TTM for reperfusion injury of the heart	Finland	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/FI1	TTM for reperfusion injury of the brain	Finland	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/FR	TTM for reperfusion injury of the heart	France	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/FR1	TTM for reperfusion injury of the brain	France	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered

REP08666EP/FR2	TTM for reperfusion injury of the kidney - Magnus Oxygen	France	30/03/2011	14194820.8	2842562	27/04/2016	2842562	EP National Phase Entered
REP08666EP/GB	TTM for reperfusion injury of the heart	United Kingdom	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/GB1	TTM for reperfusion injury of the brain	United Kingdom	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/GB2	TTM for reperfusion injury of the kidney - Magnus Oxygen	United Kingdom	30/03/2011	14194820.8	2842562	27/04/2016	2842562	EP National Phase Entered
REP08666EP/HU	TTM for reperfusion injury of the heart	Hungary	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/HU1	TTM for reperfusion injury of the brain	Hungary	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/IT	TTM for reperfusion injury of the heart	Italy	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/IT1	TTM for reperfusion injury of the brain	Italy	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/IT2	TTM for reperfusion injury of the kidney - Magnus Oxygen	Italy	30/03/2011	14194820.8	2842562	27/04/2016	2842562	Granted/Registered
REP08666EP/LT	TTM for reperfusion injury of the heart	Lithuania	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/LT1	TTM for reperfusion injury of the brain	Lithuania	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/MK	TTM for reperfusion injury of the heart	Macedonia (F.Y.R.O.M)	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/MK1	TTM for reperfusion injury of the brain	Macedonia (F.Y.R.O.M)	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/NL	TTM for reperfusion injury of the heart	Netherlands	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/NL1	TTM for reperfusion injury of the brain	Netherlands	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered

REP08666EP/NL2	TTM for reperfusion injury of the kidney - Magnus Oxygen	Netherlands	30/03/2011	14194820.8	2842562	27/04/2016	2842562	Granted/Registered
REP08666EP/NO	TTM for reperfusion injury of the heart	Norway	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/NO1	TTM for reperfusion injury of the brain	Norway	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/PL	TTM for reperfusion injury of the heart	Poland	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/PL1	TTM for reperfusion injury of the brain	Poland	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/PT	TTM for reperfusion injury of the heart	Portugal	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/PT1	TTM for reperfusion injury of the brain	Portugal	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/SE	TTM for reperfusion injury of the heart	Sweden	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/SE1	TTM for reperfusion injury of the brain	Sweden	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/SE2	TTM for reperfusion injury of the kidney - Magnus Oxygen	Sweden	30/03/2011	14194820.8	2842562	27/04/2016	2842562	Granted/Registered
REP08666EP/SI	TTM for reperfusion injury of the heart	Slovenia	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/SI1	TTM for reperfusion injury of the brain	Slovenia	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/SK	TTM for reperfusion injury of the heart	Slovakia	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered
REP08666EP/SK1	TTM for reperfusion injury of the brain	Slovakia	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP/TR	TTM for reperfusion injury of the heart	Turkey	30/03/2011	11716626.4	2552461	17/12/2014	2552461	EP National Phase Entered

REP08666EP/TR1	TTM for reperfusion injury of the brain	Turkey	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP National Phase Entered
REP08666EP1	TTM for reperfusion injury of the heart - Magnus Oxygen	European Patent Office	30/03/2011	12189630.2	2556834	26/11/2014	2556834	EP Granted
REP08666EP2	TTM for reperfusion injury of the kidney - Magnus Oxygen	European Patent Office	30/03/2011	14194820.8	2842562	27/04/2016	2842562	EP Granted
REP08666EP3	TTM for peripheral artery disease	European Patent Office	30/03/2011					Never filed
REP08666GB	TTM for reperfusion injury of the heart - Magnus Oxygen	United Kingdom	30/03/2010	1005394.0				Abandoned by client
REP08666JP	TTM for reperfusion injury of the heart	Japan	30/03/2011	2013-501947	2013-523709	09/01/2015	5674917	Granted/Registered
REP08666JP1	TTM for reperfusion injury of the brain	Japan	30/03/2011	2014-258628	2015-57450	11/11/2016	6038867	Granted/Registered
REP08666QQ	TTM for reperfusion injury of the heart - Magnus Oxygen	Miscellaneous						Miscellaneous matter underway
REP08666US	TTM for reperfusion injury	United States of America	30/03/2011	13/630180	2013-0177659			Examination report received
REP08666WO	TTM for reperfusion injury	World Intellectual Property Organisation	30/03/2011	PCT/GB2011/050653	WO2011/121354			Case Completed
	Crystalline Diethyleamine tetrathiomolybdate and its Pharmaceutical Uses	United States of America	21/10/2016	62/410.888				Filed